Trenchant Biosystems released internal and third‑party validation data for its AutoCell automated cell‑and‑gene‑therapy (CGT) manufacturing prototype, asserting it can reduce vein‑to‑vein timelines from six weeks to 2.5 days, increase gene‑modified cell yields sevenfold and cut costs by up to 80%. The company reported controlled T‑cell selection, activation and transduction operations across five donor apheresis runs and external validation of unit operations by Invetech. Trenchant said the platform could enable CGTs to scale beyond niche use by automating QC and in‑process testing, potentially making first‑line use of CGTs commercially feasible if these prototype results hold in regulated, multi‑site validations.